Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Names Hemophilia Drug as Newest Pipeline Candidate

Premium

Alnylam Pharmaceuticals announced this week that it has added ALN-APC, an siRNA-based treatment for hemophilia, to its formal drug-development pipeline.

Earlier this year, Alnylam CEO John Maraganore said that the company would select two new drug programs before the end of the year, and was considering several diseases, including thalassemia, hemophilia, and hereditary angioedema (GSN 5/12/2011).

The newest program targets protein C, a natural anticoagulant pathway. The drug candidate is designed to boost levels of thrombin generation and reduce frequency of bleeding in hemophiliacs.

“With the opportunity to measure clinically meaningful biomarkers in a phase I trial [of ALN-APC], we expect to achieve early human data followed by execution on what we believe are clear and rapid development and commercialization paths,” Alnylam CMO Akshay Vaishnaw said in a statement. “We anticipate advancing this program into clinical development in 2013."

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.